Butterfly Network Inc Dossier - Source-backed chat

Butterfly Network Inc

BFLYNYSE

SectorHealth Care

IndustryMedical Devices

Beta (adjusted)1.72

Intrinsic Value $3.49median of 2 methodsbased on filings through 30 Jun 2026

Market Price $8.53Price as of 1 Oct 2026

Significantly overvaluedIntrinsic value is 59% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (-59%)

Data confidence Sign in to view data confidence

Market Cap $2.3B

Enterprise Value $2.1B

Shares Outstanding 264.8M diluted

Next Earnings Date30 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Butterfly Network, Inc. is successfully transitioning from a pure-play hardware point-of-care ultrasound (POCUS) provider to a high-margin platform business. This evolution is driven by three core growth engines: global scaling of POCUS hardware (such as the iQ3), the commercialization of Home & Community Care (Butterfly Home), and high-margin licensing of its proprietary Ultrasound-on-Chip™ technology via Butterfly Embedded. The company's strategic co-development partnership with Midjourney, which is expected to deliver up to $74 million over five years, has significantly accelerated top-line growth and gross margin expansion. With Q1 2026 revenue growing 25% year-over-year and gross margins reaching 68.9%, Butterfly is demonstrating disciplined execution and a clear path toward operating breakeven.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$5.25

Mean target$9.31

High · most bullish analyst$11.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.2520%

Slower-than-expected enterprise software adoption for Compass AI, delays in the statewide rollout of Butterfly Home, or a temporary pause in new Embedded partner signings. This scenario assumes revenue growth slows to the mid-teens, resulting in an extended cash burn runway and delaying adjusted EBITDA profitability past 2028.

Base CaseCentral scenario

$9.3150%

Matches the consensus mean

Butterfly executes in line with its reaffirmed FY 2026 guidance, delivering revenue between $117 million and $121 million and narrowing its adjusted EBITDA loss to between $21 million and $25 million. The Midjourney partnership continues to contribute steady licensing revenue, and the next-generation Apollo chip remains on track for launch in 2027.

Bull CaseUpside scenario

$11.0030%

Rapid global adoption of the iQ3 probe, accelerated commercialization of Butterfly Home with statewide nursing deployments in H2 2026, and the signing of multiple new high-margin Butterfly Embedded partnerships. This scenario assumes the company beats the high end of its FY 2026 revenue guidance ($121 million) and achieves adjusted EBITDA breakeven ahead of schedule in late 2027.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary Ultrasound-on-Chip™ semiconductor platform protected by over 600 patents, creating a significant competitive moat.
High-margin revenue mix shift driven by Butterfly Embedded licensing and Compass AI enterprise software subscriptions, lifting gross margins to 68.9%.
Strong balance sheet with $138.0 million in cash and cash equivalents as of March 31, 2026, providing a solid runway to fund operations.
Strategic co-development partnership with Midjourney worth up to $74 million over five years, validating the commercial value of the chip platform.

Key Investment Risks

High historical cash burn and ongoing net losses ($12.7 million in Q1 2026) require disciplined expense management to avoid future dilution.
Adoption risks in the highly conservative medical community, where transitioning from traditional cart-based systems to handheld POCUS can be slow.
Execution risks associated with the commercial launch of the Home & Community Care segment (Butterfly Home) in H2 2026.

Thesis Invalidation Triggers

A significant delay or cancellation of expected milestone payments under the Midjourney co-development agreement.
Quarterly gross margins falling back below 60%, indicating a loss of pricing power or a reversal of the high-margin Embedded revenue mix.
Failure to launch the next-generation Apollo chip platform on schedule.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.